MOUNTAIN VIEW, Calif., Jan. 26 /PRNewswire/ -- Based on its recent analysis of the ophthalmic pharmaceuticals market, Frost & Sullivan recognizes ESBATech with the 2009 North American Frost & Sullivan Technology Innovation of the Year Award for its work in developing antibody fragments. The smaller size of ESBATech's proprietary single-chain antibody fragment therapeutics addresses and overcomes many of the challenges associated with whole antibodies when treating diseases of the eye.
Unlike monoclonal antibodies that contain the Fc part of the antibody that triggers immune responses, antibody fragments consist of only the naturally occurring antigen-binding pocket of the monoclonal antibody. This can be advantageous for disease indications such as age-related macular degeneration (AMD) and uveitis, where no immune response is required. For this reason, endogenous proteins make excellent targets for these novel biologics.
"While antibody fragments are an appealing new therapy class, limitations such as poor production yields due to low stability, immunogenicity due to their high proclivity to aggregate, and a short half-life in the blood stream have hindered their success in preclinical and clinical trials," says Frost & Sullivan Research Analyst Misty Hughes. "In response, ESBATech developed its cutting-edge, repeatable-antigen independent screening platform, Immuna(R), for selecting and optimizing highly-stable, single-chain antibody fragments (scFv) without any phage display."
ESBATech's successful screening and characterization of all 1.5 million naturally occurring antibody fragment frameworks resulted in highly-stable, single-chain antibody fragments. These drug-like fragments are ideal for pioneering therapeutic interventions that requ
|SOURCE Frost & Sullivan|
Copyright©2009 PR Newswire.
All rights reserved